Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites.

Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, Rogowski-Lehmann N, Langton K, Tsourdi E, Pęczkowska M, Fliedner S, Deutschbein T, Megerle F, Timmers HJLM, Sinnott R, Beuschlein F, Fassnacht M, Januszewicz A, Lenders JWM.

Clin Chem. 2018 Aug 10. pii: clinchem.2018.291369. doi: 10.1373/clinchem.2018.291369. [Epub ahead of print]

PMID:
30097498
2.

Thy-1 (CD90) promotes bone formation and protects against obesity.

Picke AK, Campbell GM, Blüher M, Krügel U, Schmidt FN, Tsourdi E, Winzer M, Rauner M, Vukicevic V, Busse B, Salbach-Hirsch J, Tuckermann JP, Simon JC, Anderegg U, Hofbauer LC, Saalbach A.

Sci Transl Med. 2018 Aug 8;10(453). pii: eaao6806. doi: 10.1126/scitranslmed.aao6806.

PMID:
30089635
3.

Apalutamide and Metastasis-free Survival in Prostate Cancer.

Rachner TD, Tsourdi E, Hofbauer LC.

N Engl J Med. 2018 Jun 28;378(26):2541-2. doi: 10.1056/NEJMc1806189. No abstract available.

PMID:
29952180
4.

Certainties and Uncertainties About Denosumab Discontinuation.

Tsourdi E, Zillikens MC.

Calcif Tissue Int. 2018 Jul;103(1):1-4. doi: 10.1007/s00223-018-0436-y. Epub 2018 Jun 15. Review. No abstract available.

PMID:
29926143
5.

[Impact of thyroid diseases on bone].

Tsourdi E, Lademann F, Siggelkow H.

Internist (Berl). 2018 May 9. doi: 10.1007/s00108-018-0436-z. [Epub ahead of print] Review. German.

PMID:
29744522
6.

Denosumab: a new treatment option for glucocorticoid-induced osteoporosis.

Tsourdi E, Hofbauer LC.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):428-429. doi: 10.1016/S2213-8587(18)30097-4. Epub 2018 Apr 6. No abstract available.

PMID:
29631783
7.

Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.

Tsourdi E, Rachner TD, Hofbauer LC.

N Engl J Med. 2018 Jan 11;378(2):195. doi: 10.1056/NEJMc1714810. No abstract available.

PMID:
29322753
8.

Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report.

Kroemer TM, Erler A, Tsourdi E, Gruber M, Tselmin S, Julius U, Aringer M, Hofbauer LC, Rachner TD.

Diabetes Care. 2018 Mar;41(3):e23-e24. doi: 10.2337/dc17-1974. Epub 2017 Dec 27. No abstract available.

PMID:
29282202
9.

Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.

Tsourdi E, Lademann F, Ominsky MS, Rijntjes E, Köhrle J, Misof BM, Roschger P, Klaushofer K, Hofbauer LC, Rauner M.

Endocrinology. 2017 Nov 1;158(11):3765-3777. doi: 10.1210/en.2017-00247.

PMID:
28973221
10.

Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC.

Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5. Review.

PMID:
28789921
11.

[New Osteoanabolic Therapies for Osteoporosis].

Tsourdi E, Lademann F, Hofbauer LC.

Dtsch Med Wochenschr. 2017 Apr;142(7):475-478. doi: 10.1055/s-0042-122721. Epub 2017 Apr 7. German. No abstract available.

PMID:
28388741
12.

[Diagnostics in osteology].

Jakob F, Genest F, Seefried L, Tsourdi E, Lapa C, Hofbauer LC.

Internist (Berl). 2016 Jul;57(7):631-7. doi: 10.1007/s00108-016-0081-3. Review. German.

PMID:
27307159
13.

Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts.

Tsourdi E, Wallaschofski H, Rauner M, Nauck M, Pietzner M, Rettig R, Ittermann T, Völzke H, Völker U, Hofbauer LC, Hannemann A.

Osteoporos Int. 2016 Feb;27(2):719-27. doi: 10.1007/s00198-015-3276-x. Epub 2015 Aug 12.

PMID:
26264603
14.

Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1.

Tsourdi E, Rijntjes E, Köhrle J, Hofbauer LC, Rauner M.

Endocrinology. 2015 Oct;156(10):3517-27. doi: 10.1210/en.2015-1073. Epub 2015 Jul 28.

PMID:
26218891
15.

Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome.

Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Macut D, Bjekic-Macut J, Marthopoulos A, Katsikis I.

Hormones (Athens). 2015 Jul-Sep;14(3):431-7.

PMID:
26188231
16.

Graves' disease after treatment with alemtuzumab for multiple sclerosis.

Tsourdi E, Gruber M, Rauner M, Blankenburg J, Ziemssen T, Hofbauer LC.

Hormones (Athens). 2015 Jan-Mar;14(1):148-53. doi: 10.14310/horm.2002.1501.

17.

Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts.

Keller J, Catala-Lehnen P, Huebner AK, Jeschke A, Heckt T, Lueth A, Krause M, Koehne T, Albers J, Schulze J, Schilling S, Haberland M, Denninger H, Neven M, Hermans-Borgmeyer I, Streichert T, Breer S, Barvencik F, Levkau B, Rathkolb B, Wolf E, Calzada-Wack J, Neff F, Gailus-Durner V, Fuchs H, de Angelis MH, Klutmann S, Tsourdi E, Hofbauer LC, Kleuser B, Chun J, Schinke T, Amling M.

Nat Commun. 2014 Oct 21;5:5215. doi: 10.1038/ncomms6215.

18.

An exotic cause of exudative enteropathy.

Tsourdi E, Heidrich FM, Winzer M, Röllig C, Kirsch C, Meinel J, Baretton GB, Bornstein SR, Hofbauer LC.

Am J Case Rep. 2014 May 22;15:226-9. doi: 10.12659/AJCR.890483. eCollection 2014.

19.

Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.

Koiou E, Tziomalos K, Katsikis I, Delkos D, Tsourdi EA, Panidis D.

Hormones (Athens). 2013 Oct-Dec;12(4):559-66.

20.

Uterine volume and endometrial thickness in the early follicular phase in patients with polycystic ovary syndrome.

Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Betsas G, Tsourdi E, Katsikis I.

Endocr Pract. 2014 Jun;20(6):540-7. doi: 10.4158/EP13058.OR.

PMID:
24325993
21.

The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.

Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Katsikis I.

Clin Endocrinol (Oxf). 2014 Mar;80(3):432-8. doi: 10.1111/cen.12305. Epub 2013 Aug 28.

PMID:
23909452
22.

Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome.

Panidis D, Tziomalos K, Macut D, Kandaraki EA, Tsourdi EA, Papadakis E, Katsikis I.

Gynecol Endocrinol. 2013 Oct;29(10):926-30. doi: 10.3109/09513590.2013.819079. Epub 2013 Jul 25.

PMID:
23885694
23.

Macroglossia as the only presenting feature of amyloidosis due to MGUS.

Tsourdi E, Därr R, Wieczorek K, Röcken C, Ehehalt F, Conrad K, Platzbecker U, Hofbauer LC.

Eur J Haematol. 2014 Jan;92(1):88-9. doi: 10.1111/ejh.12163. Epub 2013 Jul 25. No abstract available.

PMID:
23799910
24.

Skeletal and soft tissue involvement in Mazabraud syndrome.

Tsourdi E, Hamann C, Hofbauer LC.

J Clin Endocrinol Metab. 2013 Aug;98(8):E1381-2. doi: 10.1210/jc.2013-2186. Epub 2013 May 20. No abstract available.

PMID:
23690310
25.

Current aspects in the pathophysiology and treatment of chronic wounds in diabetes mellitus.

Tsourdi E, Barthel A, Rietzsch H, Reichel A, Bornstein SR.

Biomed Res Int. 2013;2013:385641. doi: 10.1155/2013/385641. Epub 2013 Apr 7. Review.

26.

The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome.

Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Vosnakis C, Katsikis I.

Eur J Endocrinol. 2013 May 3;168(6):871-7. doi: 10.1530/EJE-13-0039. Print 2013 Jun.

27.

Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.

Panidis D, Tziomalos K, Chatzis P, Papadakis E, Delkos D, Tsourdi EA, Kandaraki EA, Katsikis I.

Eur J Endocrinol. 2013 Jan 17;168(2):145-52. doi: 10.1530/EJE-12-0655. Print 2013 Feb.

28.

Prevalence of metabolic syndrome in women with polycystic ovary syndrome.

Panidis D, Macut D, Tziomalos K, Papadakis E, Mikhailidis K, Kandaraki EA, Tsourdi EA, Tantanasis T, Mavromatidis G, Katsikis I.

Clin Endocrinol (Oxf). 2013 Apr;78(4):586-92. doi: 10.1111/cen.12008.

PMID:
22888988
29.

Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.

Spanos N, Tziomalos K, Macut D, Koiou E, Kandaraki EA, Delkos D, Tsourdi E, Panidis D.

Obes Facts. 2012;5(4):495-504. doi: 10.1159/000341579. Epub 2012 Jul 23.

30.

Selective glucocorticoid receptor modulation maintains bone mineral density in mice.

Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, Rauner M.

J Bone Miner Res. 2012 Nov;27(11):2242-50. doi: 10.1002/jbmr.1688.

31.

Skeletal and extraskeletal actions of denosumab.

Sinningen K, Tsourdi E, Rauner M, Rachner TD, Hamann C, Hofbauer LC.

Endocrine. 2012 Aug;42(1):52-62. doi: 10.1007/s12020-012-9696-x. Epub 2012 May 13. Review.

PMID:
22581255
32.

Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome.

Koiou E, Tziomalos K, Katsikis I, Dinas K, Tsourdi EA, Kandaraki EA, Delkos D, Papadakis E, Panidis D.

Hormones (Athens). 2012 Jan-Mar;11(1):77-85.

33.

[Innovations in the treatment of osteoporosis].

Tsourdi E, Hofbauer LC.

Dtsch Med Wochenschr. 2011 Dec;136(48):2458-60. doi: 10.1055/s-0031-1297266. Epub 2011 Nov 22. German. No abstract available.

PMID:
22109575
34.

Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.

Koiou E, Tziomalos K, Dinas K, Katsikis I, Kandaraki EA, Tsourdi E, Mavridis S, Panidis D.

Endocr J. 2012;59(1):21-9. Epub 2011 Oct 12.

35.

Denosumab for bone diseases: translating bone biology into targeted therapy.

Tsourdi E, Rachner TD, Rauner M, Hamann C, Hofbauer LC.

Eur J Endocrinol. 2011 Dec;165(6):833-40. doi: 10.1530/EJE-11-0454. Epub 2011 Aug 18. Review. Erratum in: Eur J Endocrinol. 2012 Jan;166(1):137.

36.

Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels.

Koiou E, Tziomalos K, Katsikis I, Kalaitzakis E, Kandaraki EA, Tsourdi EA, Delkos D, Papadakis E, Panidis D.

Eur J Endocrinol. 2011 Jul;165(1):63-8. doi: 10.1530/EJE-11-0144. Epub 2011 May 4.

37.

Seizures associated with zoledronic acid for osteoporosis.

Tsourdi E, Rachner TD, Gruber M, Hamann C, Ziemssen T, Hofbauer LC.

J Clin Endocrinol Metab. 2011 Jul;96(7):1955-9. doi: 10.1210/jc.2011-0418. Epub 2011 Apr 20.

PMID:
21508139
38.

The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study.

Panidis D, Tziomalos K, Koiou E, Kandaraki EA, Tsourdi E, Delkos D, Kalaitzakis E, Katsikis I.

Reprod Biol Endocrinol. 2010 Dec 9;8:151. doi: 10.1186/1477-7827-8-151.

39.

The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.

Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D.

Fertil Steril. 2009 Apr;91(4 Suppl):1427-30. doi: 10.1016/j.fertnstert.2008.06.002. Epub 2008 Aug 9.

PMID:
18692782

Supplemental Content

Loading ...
Support Center